Harbin Gloria Pharmaceuticals (002437.SZ) Earnings Analysis

Harbin Gloria Pharmaceuticals (002437.SZ) has no confirmed upcoming earnings date. Trailing P/E 15.28.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 002437.SZ next report earnings?

No confirmed upcoming earnings date is currently scheduled for 002437.SZ. This page updates as the calendar is published.

002437.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-150.0608 CNYn/an/an/a
2025-10-290.0487 CNYn/an/an/a
2025-06-300.03274 CNYn/an/an/a
2025-03-310.0266 CNYn/an/an/a
2024-12-310.02177 CNYn/an/an/a

002437.SZ valuation and analyst view

Trailing P/E15.28
Trailing EPS0.18774 CNY
Price / book2.63
Dividend yield0.00%
Market cap6.31B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Harbin Gloria Pharmaceuticals (002437.SZ)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 002437.SZ. This page updates as the calendar is published.

Did 002437.SZ beat earnings last quarter?

Consensus estimate data was not available for 002437.SZ's 2026-04-15 report.

What is 002437.SZ's current P/E ratio and EPS?

002437.SZ trades at a trailing P/E of 15.28 on trailing EPS of 0.1877394724919798 CNY.

What do analysts rate 002437.SZ?

002437.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.